Research focus

Intensive care medicine

In intensive care medicine, various plasma proteins from Biotest are already in use today, for instance as volume and protein replacement in severe injuries and burns and also for the treatment of severe bacterial infections (e.g. sepsis).

Continuing this practice, Biotest is developing the IgM and IgA-enriched polyclonal antibody preparation  trimodulin for the treatment of severe community acquired pneumonia.

Moreover, we work on innovations to improve products, for instance, to allow faster use of the blood clotting factor fibrinogen in life-threatening conditions. 

Intensive care medicine pipeline

   
  • pre
  • 1
  • 2
  • 3
  • reg
  • launch
  • lcm
 

Trimodulin
BT-086

Severe community acquired pneumonia

Trimodulin

BT-086
Severe community acquired pneumonia

 

Fibrinogen
BT-524

Congenital fibrinogen deficiency

Fibrinogen

BT-524
Congenital fibrinogen deficiency

 

Fibrinogen
BT-524

Acquired Fibrinogen Deficiency

Fibrinogen

BT-524
Acquired Fibrinogen Deficiency